1-3 of 3
Claudio Dansky Ullmann
Close
Sort by
Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Owen A. O'Connor, MD PhD, Muhit Özcan, MD, Eric D. Jacobsen, MD, Josep Maria Roncero Vidal, MD, Judith Trotman, MBChB, Judit Demeter, MD PhD DsC, Tamás Masszi, MD, Juliana Pereira, MD PhD, Radhakrishnan Ramchandren, MD, Francesco A. d'Amore, MD PhD, Francine Foss, MD, Won-Seog Kim, MD PhD, John P. Leonard, MD, Carlos Sérgio Chiattone, MD PhD, Pier Luigi Zinzani, MD PhD, Hua Liu, PhD, JungAh Jung, PhD, Xiaofei Zhou, PhD, E. Jane Leonard, MSc, Claudio Dansky Ullmann, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2015) 126 (23): 341.
https://doi.org/10.1182/blood.V126.23.341.341
Published: 2015
Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2013) 122 (21): 3027.
https://doi.org/10.1182/blood.V122.21.3027.3027
Published: 2013
Journal Articles

Adoptive Transfer of Anti-CD3–Activated CD4 + T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity

Mark L. Saxton, Dan L. Longo, Holly E. Wetzel, Henry Tribble, W. Gregory Alvord, Larry W. Kwak, Arnold S. Leonard, Claudio Dansky Ullmann, Brendan D. Curti, Augusto C. Ochoa
Journal: Blood
Blood (1997) 89 (7): 2529–2536.
https://doi.org/10.1182/blood.V89.7.2529
Published: 1997